The RxTx Highlights program is a continuing education program developed by the Canadian Pharmacists Association (CPhA) and the Information Technology Primary Care Research Group at McGill University. In this program, the CPhA emails weekly treatment recommendations (Highlights), based on their online clinical resource RxTx, to their members. Participating CPhA members are given the opportunity to rate the relevance, cognitive impact, intention to use and expected patient health benefits for each Highlight received using the Information Assessment Method (www.mcgill.ca/iam), in exchange for continuing education credits.
For this annual report, all the ratings provided by participants in 2016 were analyzed, and the top 5 most beneficial Highlights were identified ( Table 1 ). The analysis used the Benefit of Information Index (BII), which considers the proportion of ratings indicating an expected health benefit for at least 1 patient and half of the proportion of ratings indicating a possible health benefit for at least 1 patient. 3 Crowdsourcing is a force multiplier, which allows the traditional "ask-the-user" approach to reach a wider audience. 4, 5 One potential shortcoming of using crowdsourcing, however, is the unperceived continuing education needs of pharmacists. For example, if pharmacists were unaware that about 50% of their patients may have lower urinary tract symptoms, they would rate a guideline for that condition much lower because they do not perceive there is a problem.
Through this article, the insight obtained from the ratings of participating CPhA members may be useful to all pharmacists, as large groups can be collectively wise in identifying relevant information. NACI recommendations regarding egg-allergic individuals have evolved over the past several influenza seasons based on emerging clinical evidence. Egg-allergic adults and children may be vaccinated against influenza using a single, full dose of injectable trivalent or quadrivalent inactivated vaccine without a prior influenza skin test, irrespective of the immunization setting or of a past severe reaction to egg. Due to a lack of data at the time the current NACI statement was issued, the live attenuated intranasal influenza vaccine (LAIV) is not recommended for persons with a documented egg allergy. A study of 779 egg-allergic children aged 2-18 years, published subsequent to the 2015-2016 NACI statement, demonstrated the LAIV is well tolerated in youth with a history of egg allergy. Approximately 35% of subjects in the study population reported a history of anaphylaxis to egg and >50% had been diagnosed with asthma or recurrent wheeze. LAIV could be considered as an alternative for young patients with a history of egg allergy and needle phobia. It is expected that NACI recommendations will continue to evolve as the evidence base grows in this area. As with all vaccines, immunization providers should have the necessary equipment to respond to vaccine emergencies at all times. 
